title: [Prognostic factors of immunosuppressive therapy in children acquired aplastic anemia].
abstract: OBJECTIVE
  To investigate prognostic factors of immunosuppressive therapy (IST) in children acquired severe aplastic anemia(SAA).
  
  
  METHODS
  Data of 56 consecutive children cases with SAA who had received rabbit anti-thymocyte globulin (R-ATG) [3-5 mg/( kg x d) x 5 d] and cyclosporine A (CSA) from January 2000 to June 2006 were retrospectively analyzed. No repeated courses of R-ATG were given for nonresponders. All the patients also received stanozolol or testosterone propionate. The dose of CSA was adjusted to maintain trough drug levels above 100 microg/L and peak drug levels above 300 microg/L.
  
  
  RESULTS
  The overall response rate to the immunosuppressive therapy (IST) was 62.5% and the complete remission rate was 37.5%. The 5-year overall survival for IST regimens was 66.27% +/- 6.84%, patients who had infections when using ATG had significantly lower response and higher mortality. Patients whose nucleated erythrocyte population in bone marrow was > or =10% had good prognosis. Patients whose granulocytes population in bone marrow was > or =10% had lower mortality.
  
  
  CONCLUSIONS
  Patients who had infections when using ATG had significantly lower response and higher mortality. Patients whose nucleated erythrocyte population in bone marrow was > or =10% had good prognosis.
authors: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.
authors: Shu-chun
authors: SC
authors: Wang
authors: Xiao-juan
authors: XJ
authors: Chen
authors: Yao
authors: Y
authors: Zou
authors: Wen-yu
authors: WY
authors: Yang
authors: Tian-feng
authors: TF
authors: Liu
authors: Li
authors: L
authors: Zhang
authors: Yu-mei
authors: YM
authors: Chen
authors: Ye
authors: Y
authors: Guo
authors: Xiao-fan
authors: XF
authors: Zhu
mesh_terms: D000293:Adolescent; D000741:Anemia, Aplastic / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D000818:Animals; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D011379:Prognosis; D011817:Rabbits; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016572:Cyclosporine